{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:14:30Z","timestamp":1791000870086,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s10792-017-0499-1","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T11:48:43Z","timestamp":1489578523000},"page":"607-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Evaluation of vitreous levels of advanced glycation end products and angiogenic factors as biomarkers for severity of diabetic retinopathy"],"prefix":"10.1007","volume":"38","author":[{"given":"Makiko","family":"Katagiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiko","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Uchigata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"499_CR1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"499_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1056-8727(01)00155-6","volume":"15","author":"T Yuuki","year":"2001","unstructured":"Yuuki T, Kanda T, Kimura Y et al (2001) Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complicat 15:257\u2013259","journal-title":"J Diabetes Complicat"},{"key":"499_CR3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajo.2006.07.032","volume":"143","author":"MG Petrovic","year":"2007","unstructured":"Petrovic MG, Korosec P, Kosnik M, Hawlina M (2007) Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol 143:175\u2013176","journal-title":"Am J Ophthalmol"},{"key":"499_CR4","first-page":"3576","volume":"41","author":"RF Gariano","year":"2000","unstructured":"Gariano RF, Nath AK, D\u2019Amico DJ, Lee T, Sierra-Honigmann MR (2000) Elevation of vitreous leptin in diabetic retinopathy and retinal detachment. Invest Ophthalmol Vis Sci 41:3576\u20133581","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"499_CR5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.eye.6702011","volume":"20","author":"D Maberley","year":"2006","unstructured":"Maberley D, Cui JZ, Matsubara JA (2006) Vitreous leptin levels in retinal disease. Eye 20:801\u2013804","journal-title":"Eye"},{"key":"499_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00006982-200402000-00005","volume":"24","author":"C Hernandez","year":"2004","unstructured":"Hernandez C, Lecube A, Castellanos JM et al (2004) Intravitreous leptin concentrations in patients with proliferative diabetic retinopathy. Retina 24:30\u201335","journal-title":"Retina"},{"key":"499_CR7","first-page":"109","volume":"78","author":"A Khaliq","year":"1998","unstructured":"Khaliq A, Foreman D, Ahmed A et al (1998) Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 78:109\u2013116","journal-title":"Lab Invest"},{"key":"499_CR8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00125-006-0539-2","volume":"50","author":"N Miyamoto","year":"2007","unstructured":"Miyamoto N, de Kozak Y, Jeanny JC et al (2007) Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50:461\u2013470","journal-title":"Diabetologia"},{"key":"499_CR9","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695\u20131705","journal-title":"Ophthalmology"},{"key":"499_CR10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.eye.6702980","volume":"23","author":"JF Arevalo","year":"2009","unstructured":"Arevalo JF, Wu L, Sanchez JG et al (2009) Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy; 6-months follow-up. Eye 23:117\u2013123","journal-title":"Eye"},{"key":"499_CR11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2796.2002.00932.x","volume":"251","author":"H Vlassara","year":"2002","unstructured":"Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251:87\u2013101","journal-title":"J Intern Med"},{"key":"499_CR12","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1167\/iovs.04-1409","volume":"46","author":"GR Barile","year":"2005","unstructured":"Barile GR, Pachydaki SI, Tari SR et al (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46:2916\u20132924","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"499_CR13","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2174\/1381612054367300","volume":"11","author":"S Yamagishi","year":"2005","unstructured":"Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279\u20132299","journal-title":"Curr Pharm Des"},{"key":"499_CR14","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.diabres.2007.01.030","volume":"77","author":"Y Yamamoto","year":"2007","unstructured":"Yamamoto Y, Yonekura H, Watanabe T et al (2007) Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 77:S30\u2013S40","journal-title":"Diabetes Res Clin Pract"},{"key":"499_CR15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/156652406776894536","volume":"6","author":"T Sato","year":"2006","unstructured":"Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGE) theory in diabetic complication. Curr Mol Med 6:351\u2013358","journal-title":"Curr Mol Med"},{"key":"499_CR16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1006\/bbrc.2001.6312","volume":"290","author":"S Yamagishi","year":"2002","unstructured":"Yamagishi S, Amano S, Inagaki Y et al (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 290:973\u2013978","journal-title":"Biochem Biophys Res Commun"},{"key":"499_CR17","doi-asserted-by":"crossref","first-page":"8723","DOI":"10.1074\/jbc.272.13.8723","volume":"272","author":"S Yamagishi","year":"1997","unstructured":"Yamagishi S, Yonekura H, Yamamoto Y et al (1997) Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 272:8723\u20138730","journal-title":"J Biol Chem"},{"key":"499_CR18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3892\/mmr.2012.1152","volume":"7","author":"J Ai","year":"2013","unstructured":"Ai J, Liu Y, Sun JH (2013) Advanced glycation end-products stimulate basic fibroblast growth factor expression in cultured M\u00fcller cells. Mol Med Rep 7:16\u201320","journal-title":"Mol Med Rep"},{"key":"499_CR19","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1007\/s00125-010-1900-z","volume":"53","author":"H Zong","year":"2010","unstructured":"Zong H, Ward A, Madden A et al (2010) Hyperglycaemia-induced pro-inflammatory responses by retinal M\u00fcller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 53:2656\u20132666","journal-title":"Diabetologia"},{"key":"499_CR20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bjo.2004.055053","volume":"89","author":"M Yokoi","year":"2005","unstructured":"Yokoi M, Yamagishi S, Takeuchi M et al (2005) Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 89:673\u2013675","journal-title":"Br J Ophthalmol"},{"key":"499_CR21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.exer.2005.09.022","volume":"82","author":"SI Pachydaki","year":"2006","unstructured":"Pachydaki SI, Tari SR, Lee SE et al (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82:807\u2013815","journal-title":"Exp Eye Res"},{"key":"499_CR22","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2337\/db12-1608","volume":"62","author":"Y Kaida","year":"2013","unstructured":"Kaida Y, Fukumi K, Masui T et al (2013) DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 62:3241\u20133250","journal-title":"Diabetes"},{"key":"499_CR23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mvr.2013.08.010","volume":"90","author":"Y Higashimono","year":"2013","unstructured":"Higashimono Y, Matui T, Nishino Y et al (2013) Blockade by phosphorothioate aptamers of advances glycation end products-induced damage in cultured pericytes and endothelial cells. Microvasc Res 90:64\u201370","journal-title":"Microvasc Res"},{"key":"499_CR24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000440768","volume":"54","author":"S Maeda","year":"2015","unstructured":"Maeda S, Matsui T, Ojima A et al (2015) DNA aptamer raised against advanced glycation end products prevents abnormalities in electroretinograms of experimental diabetic retinopathy. Ophthalmic Res 54:175\u2013180","journal-title":"Ophthalmic Res"},{"key":"499_CR25","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1073\/pnas.88.20.9267","volume":"88","author":"D Maglione","year":"1991","unstructured":"Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267\u20139271","journal-title":"Proc Natl Acad Sci USA"},{"key":"499_CR26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","volume":"9","author":"M Autiero","year":"2003","unstructured":"Autiero M, Waltenberger J, Communi D et al (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936\u2013943","journal-title":"Nat Med"},{"key":"499_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185","journal-title":"Angiogenesis"},{"key":"499_CR28","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1126\/science.281.5383.1683","volume":"281","author":"MR Sierra-Honigmann","year":"1998","unstructured":"Sierra-Honigmann MR, Nath AK, Murakami C et al (1998) Biological action of leptin as an angiogenic factor. Science 281:1683\u20131686","journal-title":"Science"},{"key":"499_CR29","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2337\/diabetes.53.9.2443","volume":"53","author":"E Suganami","year":"2004","unstructured":"Suganami E, Takagi H, Ohashi H et al (2004) Leptin stimulates ischemia-induced retinal neovascularization. Diabetes 53:2443\u20132448","journal-title":"Diabetes"},{"key":"499_CR30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0026-2862(03)00005-0","volume":"65","author":"S Yamagishi","year":"2003","unstructured":"Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H (2003) Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res 65:186\u2013190","journal-title":"Microvasc Res"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-017-0499-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0499-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-017-0499-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:56:08Z","timestamp":1525254968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-017-0499-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1007\/s10792-017-0499-1","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}